Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
1
20%
Ph phase_4
1
20%
Ph phase_1
1
20%
Ph phase_3
2
40%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(4)
Terminated(1)

Detailed Status

Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)

Trials by Status

completed480%
terminated120%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

NCT02106494
completedphase_2

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

NCT04557189
completedphase_4

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

NCT01636947
completedphase_3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

NCT01594749
terminatedphase_1

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

NCT02614586

Clinical Trials (5)

Showing 5 of 5 trials
NCT02106494Phase 3

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

Completed
NCT04557189Phase 2

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

Completed
NCT01636947Phase 4

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Completed
NCT01594749Phase 3

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Completed
NCT02614586Phase 1

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5